GHENT, Belgium, 17 August 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] will report its 2017 half year financial results and year-to-date business update on Thursday 24 August 2017 at 7.00 am CET.
The Ablynx management team will host a conference call on Thursday 24 August 2017 at 4.00 pm CET/10.00 am ET, which will be webcast live and may be accessed by clicking here.
If you would like to participate in the Q&A session, please dial +32(0)2 402 30 92 and use confirmation code 7237205.
Shortly after the call, a replay of the webcast and copy of the presentation will be available on the Ablynx website under http://www.ablynx.com/news/events-presentations/.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: [email protected]
Lies Vanneste
Director Investor Relations
t: +32 (0)9 262 01 37
m: +32 (0)498 05 35 79
e: [email protected]
Follow us on Twitter @AblynxABLX
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/5c224884-162f-4664-8c98-c07c8b8fd62a


Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses
OpenAI Addresses Security Vulnerability in macOS App Certification Process
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58%
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG
Bill Ackman Eyes New Fund to Bet Against Market Complacency 



